Impact of high-risk classification by FISH: An Eastern Cooperative Oncology Group (ECOG) study E4A03

British Journal of Haematology

Volumn 155, Issue 3, 2011, Pages 340-348

  Jacobus, Susanna J ^a   Kumar, Shaji ^b   Uno, Hajime ^a   van Wier, Scott A ^c   Ahmann, Greg J ^c   Henderson, Kimberly J ^b   Callander, Natalie S ^d   Williams, Michael E ^e   Siegel, David S ^f   Greipp, Philip R ^b   Rajkumar, S Vincent ^b   Fonseca, Rafael ^c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e UNIVERSITY OF VIRGINIA MEDICAL CENTER   (United States)

^f HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bortezomib; Dexamethasone; FISH; Lenalidomide; Myeloma

Indexed keywords

DEXAMETHASONE; LENALIDOMIDE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHROMOSOME 17P; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 4; COHORT ANALYSIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC RISK; HEALTH STATUS; HIGH RISK CLASSIFICATION; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; ONCOLOGY; OVERALL SURVIVAL; PATIENT CODING; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SURVIVAL TIME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; SURVIVAL ANALYSIS; THALIDOMIDE;

EID: 80053965637     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08849.x     Document Type: Article

References (28)

1. Avet-Loiseau, H., Attal, M., Moreau, P., Charbonnel, C., Garban, F., Hulin, C., Leyvraz, S., Michallet, M., Yakoub-Agha, I., Garderet, L., Marit, G., Michaux, L., Voillat, L., Renaud, M., Grosbois, B., Guillerm, G., Benboubker, L., Monocunduit, M., Thieblemont, C., Casassus, P., Caillot, D., Stoppa, A.M., Sotto, J.J., Wetterwald, M., Dumontet, C., Fuzibet, J.G., Azais, I., Dorvaux, V., Zandecki, M., Bataille, R., Minvielle, S., Harousseau, J.L., Facon, T. & Mathiot, C. (2007) Genetic abnormailities in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood, 109, 3489-3495.
2. Avet-Loiseau, H., Li, C., Magrangeas, F., Gouraud, W., Charbonnel, C., Harousseau, J.L., Attal, M., Marit, G., Mathiot, C., Facon, T., Moreau, P., Anderson, K.C., Campion, L., Munshi, N.C. & Minvielle, S. (2009) Prognostic significance of copy-number alterations in multiple myeloma. Journal of Clinical Oncology, 27, 4585-4590.
3. Avet-Loiseau, H., Leleu, X., Roussel, M., Moreau, P., Guerin-Charbonnel, C., Caillot, D., Marit, G., Benboubker, L., Voillat, L., Mathiot, C., Kolb, B., Macro, M., Campion, L., Wetterwald, M., Stoppa, A.M., Hulin, C., Facon, T., Attal, M., Minvielle, S. & Harousseau, J.L. (2010a) Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). Journal of Clinical Oncology, 28, 4630-4634.
4. Avet-Loiseau, H., Soulier, J., Fermand, J.P., Yakoub-Agha, I., Attal, M., Hulin, C., Garderet, L., Belhadj, K., Dorvaux, V., Minvielle, S., Moreau, P. & IFM and MAG groups (2010b) Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone. Leukemia, 24, 623-628.
5. Avet-Loiseau, H., Malard, F., Campion, L., Magrangeas, F., Sebban, C., Lioure, B., Decaux, O., Lamy, T., Legros, L., Fuzibet, J.G., Michallet, M., Corront, B., Lenain, P., Hulin, C., Mathiot, C., Attal, M., Facon, T., Harousseau, J.L., Minvielle, S., Moreau, P. & Intergroupe Francophone du Myélome (2011) Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? Blood, 117, 2009-2011.
6. Bladé, J., Samson, D., Reece, D., Apperley, J., Björkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S. & Vesole, D. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. British Journal of Haematology, 102, 1115-1123.
7. Cavo, M., Tacchetti, P., Patriarca, F., Petrucci, M.T., Pantani, L., Galli, M., Di Raimondo, F., Crippa, C., Zamagni, E., Palumbo, A., Offidani, M., Corradini, P., Narni, F., Spadano, A., Pescosta, N., Deliliers, G.L., Ledda, A., Cellini, C., Caravita, T., Tosi, P., Baccarani, M. & GIMEMA Italian Myeloma Network (2010) Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomized phase 3 study. Lancet, 376, 2075-2085.
8. Chng, W.J., Price-Troska, T., Gonzalez-Paz, N., Van Wier, S., Jacobus, S., Blood, E., Henderson, K., Oken, M., Van Ness, B., Greipp, P., Rajkumar, S.V. & Fonseca, R. (2007) Clinical significance of TP53 mutation in myeloma. Leukemia, 21, 582-584.
9. Decaux, O., Lodé, L., Magrangeas, F., Charbonnel, C., Gouraud, W., Jézéquel, P., Attal, M., Harousseau, J.L., Moreau, P., Bataille, R., Campion, L., Avet-Loiseau, H., Minivielle, S. & Intergroupe Francophone du Myélome (2008) Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome. Journal of Clinical Oncology, 26, 4798-4805.
10. Dispenzieri, A., Rajkumar, S.V., Gertz, M.A., Fonseca, R., Lacy, M.Q., Bergsagel, P.L., Kyle, R.A., Greipp, P.R., Witzig, T.E., Reeder, C.B., Lust, J.A., Russell, S.J., Hayman, S.R., Roy, V., Kumar, S., Zeldenrust, S.R., Dalton, R.J. & Stewart, A.K. (2007) Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clinic Proceedings, 82, 323-341.
11. Drach, J., Ackerman, J., Fritz, E., Krömer, E., Schuster, R., Gisslinger, H., DeSantis, M., Zojer, N., Fiegl, M., Roka, S., Schuster, J., Heinz, R., Ludwig, H. & Huber, H. (1998) Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood, 92, 802-809.
12. Durie, B.G., Harousseau, J.L., Miguel, J.S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., Ludwig, H., Gahrton, G., Beksac, M., Crowley, J., Belch, A., Boccadaro, M., Cavo, M., Turesson, I., Joshua, D., Vesole, D., Kyle, R., Alexanian, R., Tricot, G., Attal, M., Merlini, G., Powles, R., Richardson, P., Shimizu, K., Tosi, P., Morgan, G., Rajkumar, S.V. & International Myeloma Working Group (2006) International uniform response criteria for multiple myeloma. Leukemia, 20, 1467-1473.
13. Fonseca, R., Blood, E., Rue, M., Harrington, D., Oken, M.M., Kyle, R.A., Dewald, G.W., Van Ness, B., Van Wier, S.A., Henderson, K.J., Bailey, R.J. & Greipp, P.R. (2003) Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood, 101, 4569-4575.
14. Fonseca, R., Bergsagel, P.L., Drach, J., Shaughnessy, J., Gutierrez, N., Stewart, A.K., Morgan, G., Van Ness, B., Chesi, M., Minvielle, S., Neri, A., Barlogie, B., Kuehl, W.M., Liebisch, P., Davies, F., Chen-Kiang, S., Durie, B.G., Carrasco, R., Sezer, O., Reiman, T., Pilarski, L., Avet-Loiseau, H. & International Myeloma Working Group (2009) International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia, 23, 2210-2221.
15. Jagannath, S., Richardson, P.G., Sonneveld, P., Schuster, M.W., Irwin, D., Stadtmauer, E.A., Facon, T., Harousseau, J.L., Cowan, J.M. & Anderson, K.C. (2007) Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia, 21, 151-157.
16. Kapoor, P., Kumar, S., Fonseca, R., Lacy, M.Q., Witzig, T.E., Hayman, S.R., Dispenzieri, A., Buadi, F., Bergsagel, P.L., Gertz, M.A., Dalton, R.J., Mikhael, J.R., Dingli, D., Reeder, C.B., Lust, J.A., Russell, S.J., Roy, V., Zeldenrust, S.R., Stewart, A.K., Kyle, R.A., Greipp, P.R. & Rajkumar, S.V. (2009) Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood, 114, 518-521.
17. Kapoor, P., Fonseca, R., Rajkumar, S.V., Sinha, S., Gertz, M.A., Stewart, A.K., Bergsagel, P.L., Lacy, M.Q., Dingli, D.D., Ketterling, R.P., Buadi, F., Kyle, R.A., Witzig, T.E., Greipp, P.R., Dispenzieri, A. & Kumar, S. (2010) Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapies. Mayo Clinic Proceedings, 85, 532-537.
18. Kumar, S.K., Flinn, I., Noga, S.J., Hari, P., Rifkin, R., Callander, N., Bhandari, M., Wolf, J.L., Gasparetto, C., Krishnan, A., Grosman, D., Glass, J., Sahovic, E.A., Shi, H., Webb, I.J., Richardson, P.G. & Rajkumar, S.V. (2010) Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. Leukemia, 24, 1350-1356.
19. Mateos, M.-V., Gutierrez, N.C., Paiva, B., Oriol, A., Martinez-Lopez, J., Teruel, A.I., de Paz, R., Garcia-Larana, J., Bengoechea, E., Martin, A., Diaz-Mediavilla, J., Palomera, L., Gonzalez, Y., Hernandez, J.M., Sureda, A., Bello, J.L., Bargay, J., Penalver, F.-J., Ribera, J.-M., Martin-Mateos, M.-L., Garcia-Sanz, R., Cibeira, M.T., Martin-Ramos, M.-L., Vidriales, M.-B., Montalban, M.-A., Lahuerta, J.-J., Blade, J. & San Miguel, Sr, J.F. (2010) Clinical Outcome According to Both Cytogenetic Abnormalities (CA) Detected by Fluorescence In Situ Hibridization (FISH) and Hyperdiploidy Assessed by Flow Cytometry (FCM) In Elderly Newly Diagnosed Myeloma Patients Treated with A Bortezomib-Based Combination. Blood (ASH Annual Meeting Abstracts), 116, 309.
20. Rajkumar, S.V., Jacobus, S., Callander, N.S., Fonseca, R., Vesole, D.H., Williams, M.E., Abonour, S., Siegel, D.S., Katz, M., Greipp, P.R. & Eastern Cooperative Oncology Group (2010) Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncology, 11, 29-37.
21. Reece, D., Song, K.W., Fu, T., Roland, B., Chang, H., Horsman, D.E., Mansoor, A., Chen, C., Masih-Khan, E., Trieu, Y., Bruyere, H., Stewart, D.A. & Bahlis, N.J. (2009) Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion. Blood, 114, 522-525.
22. Reeder, C.B., Reece, D.E., Kukreti, V., Chen, C., Trudel, S., Hentz, J., Noble, B., Pirooz, N.A., Spong, J.E., Piza, J.G., Zepeda, V.H., Mikhael, J.R., Leis, J.F., Bergsagel, P.L., Fonseca, R. & Stewart, A.K. (2009) Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase III clinical trial. Leukemia, 23, 1337-1341.
23. Reeder, C.B., Reece, D.E., Kukreti, V., Chen, C., Trudel, S., Laumann, K., Hentz, J., Pirooz, N.A., Piza, J.G., Tiedemann, R., Mikhael, J.R., Bergsagel, P.L., Leis, J.F., Fonseca, R. & Stewart, A.K. (2010) Once-versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood, 115, 3416-3417.
24. Richardson, P.G., Weller, E., Lonial, S., Jakubowiak, A.J., Jagannath, S., Raje, N.S., Avigan, D.E., Xie, W., Ghobrial, I.M., Schlossman, R.L., Mazumder, A., Munshi, N.C., Vesole, D.H., Joyce, R., Kaufman, J.L., Doss, D., Warren, D.L., Lunde, L.E., Kaster, S., Delaney, C., Hideshima, T., Mitsiades, C.S., Knight, R., Esseltine, D.L. & Anderson, K.C. (2010) Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood, 116, 679-686.
25. Ross, F.M., Chiecchio, L., Dagrada, G., Protheroe, R.K., Stockley, D.M., Harrison, C.J., Cross, N.C., Szubert, A.J., Drayson, M.T., Morgan, G.J. & UK Myeloma Forum (2010) The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance. Haematologica, 95, 1221-1225.
26. San Miguel, J.F., Schlag, R., Khuageva, N.K., Dimopoulos, M.A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M.T., Palumbo, A., Samoilova, O.S., Dmosynska, A., Abdulkadyrov, K.M., Schots, R., Jiang, B., Mateos, M.V., Anderson, K.C., Essentine, D.L., Liu, K., Cakana, A., vande Velde, H., Richardson, P.G. & VISTA Trial Investigators (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. New England Journal of Medicine, 259, 906-917.
27. Shaughnessy, Jr, J.D., Zhan, F., Burington, B.E., Huang, Y., Colla, S., Hanamura, I., Stewart, J.P., Kordsmeier, B., Randolph, C., Williams, D.R., Xiao, Y., Xu, H., Epstein, J., Anaissie, E., Krishna, S.G., Cottler-Fox, M., Hollmig, K., Mohiuddin, A., Pineda-Roman, M., Tricot, G., van Rhee, F., Sawyer, J., Alsayed, Y., Walker, R., Zangari, M., Crowley, J. & Barlogie, B. (2007) A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood, 109, 2276-2284.
28. Zhan, F., Huang, Y., Colla, S., Stewart, J.P., Hanamura, I., Gupta, S., Epstein, J., Yaccoby, S., Sawyer, J., Burington, B., Anaissie, E., Hollmig, K., Pineda-Roman, M., Tricot, G., van Rhee, F., Walker, R., Zangari, M., Crowley, J., Barlogie, B. & Shaughnessy, Jr, J.D. (2006) The molecular classification of multiple myeloma. Blood, 108, 2020-2028.